{"prompt": "['Status', 'Management', 'Tolerable Grade 1-2', 'Continue lenvatinib and consider dose reduction', '(duration < 48 h)', 'Initiate treatment with an antidiarrheal agent (e.g. loperamide 4 mg followed', 'by 2 mg after each episode of diarrhea with maximum 16 mg loperamide per', 'day)', 'Dietary modifications (e.g. small, bland meals such as the BRAT diet', '[bananas, rice, applies, toast])', 'Increase intake of isotonic fluids (1-1.5 L/day orally)', 'Reassess after 24 hours:', 'Resolving to baseline: advance diet and decrease antidiarrheal', 'treatment after 12 h without diarrhea', 'Not resolving: Continue/resume antidiarrheal treatment', 'Intolerable Grade 2,', 'Interrupt study treatment', 'Grade 2 > 48 h,', 'Evaluation participant in clinic', 'or > Grade 3', 'Rule out infection (e.g. C. difficile toxin, stool culture)', 'Administer antibiotics as needed (e.g. if fever or evidence of', 'neutropenic enterocolitis)', 'Administer fluids (1-1.5 L/day orally or IV) for hydration', 'Correct electrolyte abnormalities if present', 'Consider hospitalization and IV hydration for grade 3-4 diarrhea', 'Re-assess after 24 h', 'Resolving to baseline or Grade 1: consider restarting study', 'treatment at reduced dose', 'Not resolving: Start and or continue antidiarrheal treatment.', 'Consider starting or adding second line antidiarrheal or referral to', 'gastroenterologist', '5.2.2.2.8.3 Nausea and Vomiting', 'Treat with antiemetic agents as clinically appropriate. Administer supportive care including PO', 'or IV fluids and electrolyte supplementation as indicated.', '5.2.2.2.9 Management of Thyroid Dysfunction', 'Hypothyroidism has been reported in patients treated with lenvatinib. Thyroid function, T3, T4', 'and TSH should be monitored serially as per the Trial Flow Chart (Section 6.0). Hypothyroidism', 'should be treated according to standard medical practice to maintain euthyroid state.', '5.2.2.2.10 Management of Posterior Reversible Encephalopathy Syndrome (PRES)', 'Events of reversible posterior leukoencephalopathy syndrome (RPLS), also known as posterior', 'reversible encephalopathy syndrome (PRES), have been reported (<1%) in patients treated with', 'lenvatinib. PRES is a neurological disorder that can present with headache, seizure, lethargy,', 'confusion, altered mental function, blindness, and other visual or neurological disturbances. Mild', 'to severe hypertension may be present. Magnetic resonance imaging is necessary to confirm the', 'diagnosis of PRES. Appropriate measures should be taken to control blood pressure.', 'Page 23', 'Version Date: 02/09/2020']['In patients with signs or symptoms of PRES, dose interruptions, adjustments, or discontinuation', 'may be necessary as per Table 3 (Dose Modifications for Lenvatinib Treatment-Related', 'Toxicity).', '5.2.2.2.11 Management of Hypocalcemia', 'Hypocalcemia has been reported in patients taking lenvatinib. Calcium is to be monitored', 'regularly as per the Trial Flow Chart (Section 6.0) and more frequently if clinically necessary.', 'Hypocalcemia should be treated per institutional guidelines (e.g., using, as appropriate, calcium,', 'magnesium, and Vitamin D supplementation) until resolution. Interrupt and adjust lenvatinib', 'dosing as necessary depending on severity, presence of ECG changes, and persistence of', 'hypocalcemia.', '5.2.3 Pembrolizumab', 'Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks (+/-3', 'days). Sites should make every effort to target infusion timing to be as close to 30 minutes as', 'possible. However, given the variability of infusion pumps from site to site, a window of -5', 'minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min). The', 'Pharmacy Manual contains specific instructions for the preparation of the pembrolizumab', 'infusion fluid and administration of infusion solution.', 'Pembrolizumab may be provided as a sterile, preservative-free, white to off-white lyophilized', 'powder in single-use vials. Each vial will be reconstituted and diluted for intravenous infusion.', 'Each 2 mL of reconstituted solution contains 50 mg of pembrolizumab and is formulated in', 'L-', 'histidine (3.1 mg), polysorbate-80 (0.4 mg), sucrose (140 mg). The solution may contain', 'hydrochloric acid/sodium hydroxide to adjust pH to 5.5.', 'Pembrolizumab will be provided as a sterile, preservative-free, clear to slightly opalescent,', 'colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial', 'contains 100 mg of pembrolizumab in 4 mL of solution. Each 1 mL of solution contains 25 mg', 'of pembrolizumab and is formulated in: L-histidine (1.55 mg), polysorbate 80 (0.2 mg), sucrose', '(70 mg), and Water for Injection.', '5.2.3.1 Dose Modification and Toxicity Management for Immune-Related AEs Associated', 'with pembrolizumab', 'AEs associated with pembrolizumab exposure may represent an immunologic etiology. These', 'immune-related AEs (irAEs) may occur shortly after the first dose or several months after the', 'last dose of pembrolizumab treatment and may affect more than on body system simultaneously.', 'Therefore, early recognition and initiation of treatment is critical to reduce complications. Based', 'on existing clinical study data, most irAEs were reversible and could be managed with', 'interruptions of pembrolizumab, administration of corticosteroids and/or other supportive care.', 'For suspected irAEs, ensure adequate evaluation to confirm etiology or exclude other causes.', 'Additional procedures or tests such as bronchoscopy, endoscopy, skin biopsy may be included as', 'part of the evaluation. Based on the severity of irAEs, withhold or permanently discontinue', 'Page 24', 'Version Date: 02/09/2020']\n\n###\n\n", "completion": "END"}